{"product_id":"sanofi-bcg-matrix","title":"Sanofi Boston Consulting Group Matrix","description":"\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored analysis for the featured company’s product portfolio\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise BCG Matrix that simplifies strategic decisions for Sanofi's diverse portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eSanofi BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThis preview showcases the complete Sanofi BCG Matrix report you'll get. It's the same, fully-formatted document, prepared for immediate strategic application. No alterations; it’s yours to download and use instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003ch2\u003eBCG Matrix Template\u003c\/h2\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSanofi's product portfolio spans diverse markets. Its BCG Matrix reveals product growth rates \u0026amp; market share. Understanding these dynamics is crucial for strategic decisions. Identify stars, cash cows, dogs, and question marks within Sanofi's offerings. This framework helps optimize resource allocation for maximum impact. Gain a competitive edge. Purchase the full BCG Matrix for detailed analysis and actionable strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDupixent (Dupilumab)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDupixent is a Star for Sanofi, fueled by robust growth in the atopic dermatitis market and beyond. Sales surged, reaching €3.5 billion in Q1 2025, a 20.3% increase. Sanofi's strategic investments aim to maintain market leadership and explore new applications. It's projected to hit around €22 billion in sales by 2030.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eALTUVIIIO\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALTUVIIIO, a hemophilia A drug, is a Star in Sanofi's BCG matrix. It achieved €251M in sales in Q1 2025, with over 87% in the US. Sanofi expects it to be a blockbuster product in 2025. This reflects high growth and strong market acceptance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBeyfortus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBeyfortus, Sanofi's RSV vaccine, is a Star in their BCG Matrix. In Q1 2024, it significantly boosted sales, reaching €284 million. The vaccine is protecting infants in around 25 countries. Beyfortus is expected to keep sales high in 2025, driving overall growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmlitelimab\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmlitelimab, an anti-OX40L mAb, is a key asset for Sanofi, currently in four Phase III trials. This highlights Sanofi's strategic focus on its pipeline for growth. The positive reception of its anti-OX40L mechanism is crucial. Sanofi's innovation efforts are important to stay competitive.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eAmlitelimab is in Phase III trials.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eKey opinion leaders are excited.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFocus on innovation is important.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSanofi aims to strengthen its position.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFrexalimab\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFrexalimab, an anti-CD40L antibody, is in mid-stage trials for multiple sclerosis and is a 'Star' asset for Sanofi. Sanofi is boosting R\u0026amp;D, aiming to maximize its pipeline, focusing on innovative medicines. The company plans a 50% increase in Phase 3 studies from 2023 to 2025. Frexalimab's potential is significant for Sanofi's future growth. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePipeline Focus:\u003c\/strong\u003e Prioritizing first- or best-in-class assets.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eR\u0026amp;D Investment:\u003c\/strong\u003e Increased focus to unlock pipeline potential.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePhase 3 Expansion:\u003c\/strong\u003e 50% rise in Phase 3 studies by 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Goal:\u003c\/strong\u003e Deliver innovative medicines.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSanofi's Q1 2025: Dupixent Leads, Strong Growth!\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSeveral Sanofi products are \"Stars,\" indicating high growth and market share. Dupixent led, with €3.5B Q1 2025 sales, up 20.3%. ALTUVIIIO and Beyfortus also performed well, driving overall revenue. These products showcase Sanofi's focus on innovation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSales Q1 2025 (EUR)\u003c\/th\u003e\n\u003cth\u003eGrowth Driver\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDupixent\u003c\/td\u003e\n\u003ctd\u003e€3.5B\u003c\/td\u003e\n\u003ctd\u003eMarket expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eALTUVIIIO\u003c\/td\u003e\n\u003ctd\u003e€251M\u003c\/td\u003e\n\u003ctd\u003eUS Market Acceptance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeyfortus\u003c\/td\u003e\n\u003ctd\u003e€284M (Q1 2024)\u003c\/td\u003e\n\u003ctd\u003eRSV Protection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLantus (Insulin Glargine)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLantus (insulin glargine) is a key \"Cash Cow\" in Sanofi's BCG Matrix. It holds a strong market share in diabetes care. Despite biosimilar competition, Lantus remains a revenue driver. In 2022, Lantus sales were €3.1 billion, part of Sanofi's €5.3 billion diabetes segment. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolio\/Pertussis\/Hib (PPH) Primary and Booster Vaccines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolio\/Pertussis\/Hib (PPH) vaccines are crucial for Sanofi's vaccine sales. In Q1 2025, these vaccines saw a 3.8% increase in sales, fueled by higher demand. Sanofi's vaccines segment is a major focus. Sales reached €1.3 billion in Q1 2025, a rise of 11.4%. This growth was supported by positive Beyfortus phasing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneral Medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi's general medicines are a dependable source of income. This segment's varied products serve many patients, supporting steady demand. In 2024, the company's established products generated significant revenue. Sanofi invests in innovation to stay ahead in pharmaceuticals. In the third quarter of 2024, sales in this segment grew by 4.4%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Pharmaceutical Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSanofi's established pharmaceutical products are a cornerstone of its financial stability, acting as reliable cash cows. These products, with a well-established market presence, ensure consistent revenue streams. The generics segment, including established brands, generated €4.7 billion in 2022, demonstrating their ongoing importance. They provide a solid financial foundation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eGenerics segment contributed significantly to revenue in 2022.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eEstablished products benefit from strong market presence.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThese products ensure a steady revenue stream for Sanofi.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVaccines outside Beyfortus and Influenza Vaccines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBeyond the star product, Beyfortus, and influenza vaccines, Sanofi's other vaccines form a crucial cash cow. Although sales dipped in Q1 2024, they still generate significant revenue. These vaccines offer a stable financial foundation for Sanofi. The diverse portfolio helps maintain a steady income stream.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eQ1 2024 vaccine sales were impacted by the timing of deliveries.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSanofi's vaccine business overall brought in €1.2 billion in Q1 2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eDiversification helps to spread risk.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliable Revenue: Established Products Drive Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi's cash cows provide reliable revenue streams through established products. Lantus and PPH vaccines are key examples. These segments generate consistent profits. In 2024, established products sales grew by 4.4%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 Sales Growth\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLantus\u003c\/td\u003e\n\u003ctd\u003eDiabetes Care\u003c\/td\u003e\n\u003ctd\u003eStable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePPH Vaccines\u003c\/td\u003e\n\u003ctd\u003eVaccines\u003c\/td\u003e\n\u003ctd\u003e3.8% (Q1 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstablished Products\u003c\/td\u003e\n\u003ctd\u003eGeneral Medicines\u003c\/td\u003e\n\u003ctd\u003e4.4% (Q3 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAubagio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAubagio, a dog in Sanofi's BCG matrix, faces declining sales due to generic competition. This impacts its market share and revenue, presenting challenges for Sanofi. In Q4 2024, lower Aubagio sales offset gains from Dupixent and new products. Sanofi's strategic focus may shift as cheaper alternatives gain traction. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSelect Mature Products Facing Patent Expiry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanofi has mature products with expiring patents, causing sales and market share declines. The company counters this with new launches and pipeline development. Sanofi invests in R\u0026amp;D and innovation. In 2024, Sanofi's R\u0026amp;D spending was €6.1 billion. The company aims to offset patent losses through strategic initiatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProducts Impacted by Volume-Based Procurement in China\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi's sales in China face headwinds due to volume-based procurement. In Q1 2024, China sales decreased by 1.7%. This decline reflects the impact of national reimbursement drug lists. Sanofi is adjusting strategies to maintain its market presence amid regulatory changes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDivested Consumer Healthcare Business (Opella)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSanofi's strategic shift involves divesting its consumer healthcare arm, Opella, to concentrate on biopharmaceuticals. This decision aims to boost growth in oncology, immunology, and vaccines. The sale of a controlling stake in Opella to CD\u0026amp;R is expected to finalize in Q2. This strategic pivot is designed to refine Sanofi's focus and resource allocation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eSanofi's 2023 revenue was €43.07 billion.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eOpella's revenue contribution is being reallocated.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe deal with CD\u0026amp;R is a key financial restructuring move.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuserelin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBuserelin's sales have notably decreased, affecting revenue due to lower volumes. Sanofi's sales dipped by 15.7%, largely because of reduced volume. This was significantly impacted by the suspension of production in Brindisi. The 2024 net sales include €38 million from revised Global MSA clauses with Sanofi.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eSales decline impacted by reduced volume.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSanofi sales down by 15.7%.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eProduction suspension in Brindisi.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e€38 million from revised clauses.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDog Drug Sales Under Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs in Sanofi's portfolio like Aubagio face sales declines due to generics.\u003c\/p\u003e\n\u003cp\u003eBuserelin also experiences falling sales volumes, contributing to revenue pressures.\u003c\/p\u003e\n\u003cp\u003eThese products require strategic attention amid broader portfolio shifts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003eSales Impact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAubagio\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003ctd\u003eSales Decline (due to generics)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBuserelin\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003ctd\u003eSales Decline (volume-related)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003ePortfolio adjustments needed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSAR444656 (IRAK4 Degrader)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSAR444656, an IRAK4 degrader, is in Phase II trials for atopic dermatitis. Sanofi's partnership with Kymera Therapeutics on SAR444656 indicates a competitive move. Phase II data is anticipated in the first half of 2025. Sanofi's R\u0026amp;D spending in 2024 was approximately €6.5 billion. This collaboration is a potential growth area. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTolebrutinib\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTolebrutinib, a BTK inhibitor, is in late-stage development for multiple sclerosis, potentially becoming a blockbuster drug. Sanofi is strategically focusing on R\u0026amp;D, prioritizing assets like tolebrutinib. The company aims to deliver innovative medicines. In 2024, Sanofi's R\u0026amp;D spending is projected to be significant. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLunsekimig\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLunsekimig, a Sanofi asthma candidate, targets TSLP and is still in development, showing potential. Sanofi anticipates significant advancements in respiratory treatments, like lunsekimig and rilzabrutinib. In 2024, Sanofi invested heavily in R\u0026amp;D, aiming for innovative therapies. These strategic choices drive breakthrough medicines and value creation for stakeholders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVaccines Against Acne, E. Coli, and RSV (Older Adults)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSanofi is expanding its vaccine portfolio into new areas, including acne, extraintestinal pathogenic E. coli, and RSV for older adults. These vaccines are in different development phases, holding the potential to boost Sanofi's future earnings. This strategic move aligns with Sanofi's commitment to delivering innovative medicines. The focus on these vaccines shows a proactive approach to growth. In 2024, Sanofi's vaccine sales were strong, and these additions could further enhance performance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eAcne vaccine: Early stages, addressing a large market.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eE. coli vaccine: Targeting a significant unmet medical need.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eRSV vaccine (older adults): Addressing a growing health concern.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSanofi's R\u0026amp;D investments: Over €6 billion in 2024, supporting these and other projects.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDR-0201\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDR-0201, now part of Sanofi's portfolio, is a bispecific myeloid cell engager aimed at treating diseases like lupus. Sanofi acquired this asset to bolster its immunology pipeline, demonstrating a strategic move to expand its offerings. This acquisition aligns with Sanofi's focus on innovative therapies and expanding its portfolio. This is a key element for Sanofi's future growth. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eDR-0201 is a bispecific myeloid cell engager.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSanofi acquired DR-0201 to strengthen its immunology pipeline.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe asset targets difficult-to-treat diseases, such as lupus.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThis acquisition is a part of Sanofi's strategic expansion.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Potential, High-Risk Assets in the Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks in Sanofi's portfolio include products in early development, with high potential but uncertain market share. These require significant investment and strategic decisions. The potential for high returns exists if these projects succeed. This category demands vigilant monitoring and resource allocation, as per the 2024 R\u0026amp;D spendings.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eFocus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSAR444656\u003c\/td\u003e\n\u003ctd\u003ePhase II\u003c\/td\u003e\n\u003ctd\u003eAtopic Dermatitis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLunsekimig\u003c\/td\u003e\n\u003ctd\u003eDevelopment\u003c\/td\u003e\n\u003ctd\u003eAsthma\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcne Vaccine\u003c\/td\u003e\n\u003ctd\u003eEarly\u003c\/td\u003e\n\u003ctd\u003eAcne\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDR-0201\u003c\/td\u003e\n\u003ctd\u003eAcquired\u003c\/td\u003e\n\u003ctd\u003eLupus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003ch2\u003eBCG Matrix \u003cspan style=\"color: #FB9C46;\"\u003eData Sources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003cp\u003eSanofi's BCG Matrix utilizes market share analysis, sales reports, and competitor performance to strategically categorize its product portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Data-Sources.svg\" alt=\"Data Sources\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"SAE","offers":[{"title":"Default Title","offer_id":56070396510592,"sku":"sanofi-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0899\/6510\/1440\/files\/sanofi-bcg-matrix.png?v=1749422613","url":"https:\/\/swotanalysistemplates.com\/products\/sanofi-bcg-matrix","provider":"SWOT Analysis Templates","version":"1.0","type":"link"}